上海莱士血液制品股份有限公司 证券代码：002252 证券简称：上海莱士 公告编号：2024-067 关于第六届董事会第五次（临时）会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 上海莱士血液制品股份有限公司（"公司"）第六届董事会第五次（临时）会 议于 2024 年 10 月 19 日以电话和邮件方式发出会议通知，并于 2024 年 10 月 25 日上午 9 点在公司会议室召开。 本次会议应出席董事 9 名，亲自出席会议董事 9 名。本次会议由公司董事长 谭丽霞女士召集和主持，公司监事、高级管理人员等列席会议。会议的召集、召 开与表决程序符合《公司法》和《公司章程》等有关规定。与会董事经过充分研 究和讨论，审议通过了如下议案： 1、审议通过《2024 年第三季度报告》 表决结果：9票同意、0票反对、0票弃权。 《2024年第三季度报告》刊登于《证券时报》、《中国证券报》、《上海证券报》、 《证券日报》和巨潮资讯网（www.cninfo.com.cn），供投资者查阅。 特此公告。 上海莱士血液制品股份有限公司 董事会 二〇二四年十月二十九日 1 ...

证券时报e公司讯，企查查APP显示，近日，上海莱士医药有限公司成立，法定代表人为陆晖，注册资 本为1000万元，经营范围包含药品批发；药品进出口；第三类医疗器械经营；消毒器械销售；道路货物 运输；第一类医疗器械销售；保健食品（预包装）销售等。 企查查股权穿透显示，该公司由上海莱士全资持股。 ...

证券代码：002252 证券简称：上海莱士 公告编号：2024-065 上海莱士血液制品股份有限公司 关于第六届董事会第四次（临时）会议决议的公告 1、审议通过《关于第一期员工持股计划第一个锁定期解锁条件成就的议 案》 根据公司《第一期员工持股计划》以及《第一期员工持股计划管理办法》 的相关规定，公司董事会认为本员工持股计划第一个锁定期已届满且解锁条件 已成就，除 8 名持有人不符合本次员工持股计划参与条件、13 名持有人个人业 绩考核未达标、2 名持有人部分个人业绩考核未达标外，其他首次分配的持有 人解锁条件均已成就。本员工持股计划第一个锁定期可解锁的权益份额对应股 份数量为 1,197.2 万股，占公司当前总股本的 0.18%。 公司董事会薪酬与考核委员会对该事项发表了同意的意见。 表决结果：8 票同意、0 票反对、0 票弃权。关联董事 Jun Xu（徐俊）先生 回避了表决。 1 《关于第一期员工持股计划第一个锁定期解锁条件成就的公告》刊登于《证 券时报》、《中国证券报》、《上海证券报》、《证券日报》和 巨潮资讯网 （www.cninfo.com.cn），供投资者查阅。 特此公告。 本公司及董事会全体成员 ...

证券代码：002252 证券简称：上海莱士 公告编号：2024-066 上海莱士血液制品股份有限公司 关于第一期员工持股计划 第一个锁定期解锁条件成就的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 上海莱士血液制品股份有限公司（"公司"）于 2024 年 10 月 16 日召开第六 届董事会第四次（临时）会议，审议通过了《关于第一期员工持股计划第一个锁 定期解锁条件成就的议案》，董事会认为公司第一期员工持股计划第一个锁定期 解锁条件已成就。根据《关于上市公司实施员工持股计划试点的指导意见》《深 圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》《公司 第一期员工持股计划》等相关规定，现将情况公告如下： 一、第一期员工持股计划的基本情况 公司于 2023 年 7 月 28 日分别召开了第五届董事会第二十六次（临时）会议 和第五届监事会第十九次会议，审议并通过了《关于<上海莱士血液制品股份有 限公司第一期员工持股计划（草案）>及其摘要的议案》、《关于<上海莱士血液制 品股份有限公司第一期员工持股计划管理办法>的议案》等相关议案，同意公司 ...

Group 1: Company Overview - Shanghai Laishi Blood Products Co., Ltd. is a leading enterprise in the blood products industry in China, focusing on plasma source development as a key area of work [1][3] - The company currently operates 44 plasma collection stations across 11 provinces and regions, including Guangxi, Hunan, Hainan, Shaanxi, Anhui, Guangdong, Inner Mongolia, Zhejiang, Hubei, Jiangxi, and Shandong [3] Group 2: Plasma Collection and Growth - In 2023, the company collected over 1,500 tons of plasma, with growth influenced by factors such as regional coverage, local population, customs, and operational management capabilities [2] - The company employs a dual strategy for plasma source development, focusing on both existing and new sources to enhance management and promote internal growth while also pursuing mergers and acquisitions for expansion [2][3] Group 3: Market Development and Sales - The overall sales situation of the company is good, with the marketing team adopting different business models and multi-channel strategies based on the characteristics of various blood product markets [2] - Prices for blood products sold to hospitals are relatively stable, influenced by procurement policies, while prices in the external market vary based on supply and demand dynamics [2] Group 4: Product Demand Trends - The demand for albumin products in China is steadily increasing due to a growing number of applicable patients, driven by aging trends and an increase in surgical procedures [2] - High-concentration immunoglobulin products have similar clinical indications to 5% immunoglobulin but with reduced infusion times [2]

医药生物 证 券 研 究 报 告 2024 年 09 月 22 日 上海莱士 (002252) ——海尔掌舵领航，公司开启新征程 报告原因：首次覆盖 | --- | --- | |------------------------------------|-------------------------------| | 市场数据： | 2024 年 09 月 20 日 | | 收盘价（元） | 6.58 | | 一年内最高 / 最低（元） | 8.68/5.93 | | 市净率 | 1.4 | | 息率（分红 / 股价） | 0.46 | | 流通 A 股市值（百万元） | 43,657 | | 上证指数/深证成指 | 2,736.81/8,075.14 | | 注："息率"以最近一年已公布分红计算 | | | --- | --- | |------------------------------|-------------------------------| | 基础数据 : | 2024 年 06 月 30 日 | | 每股净资产（元） | 4.63 | | 资产负债率 % | 4.98 | | 总股 ...

证券代码：002252 证券简称：上海莱士 公告编号：2024-064 上海莱士血液制品股份有限公司 2024 年半年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 上海莱士血液制品股份有限公司（"公司"）于2024年8月26日召开第六届董 事会第三次会议及第六届监事会第二次会议，审议通过了《2024年中期利润分配 方案》，2024年中期利润分配方案未超过公司于2024年5月21日召开的2023年度股 东大会的授权范围，无需提交股东大会审议，现将权益分派事宜公告如下： 一、股东大会审议通过利润分配方案情况 1、公司于2024年5月21日召开2023年度股东大会，审议通过了《关于2024 年中期利润分配计划的议案》，同意由董事会根据公司的盈利情况和资金需求状 况，在分红比例不超过当期上市公司实现的净利润20%的前提下，制定公司2024 年中期利润分配方案并在规定期限内实施。 公司于2024年8月26日召开第六届董事会第三次会议及第六届监事会第二次 会议，审议通过了《2024年中期利润分配方案》，该方案为：拟以分红派息股权 登记日总股本（扣除公 ...

Group 1: Company Overview - Shanghai Laishi Blood Products Co., Ltd. is engaged in the blood products industry, focusing on both hospital and outpatient markets [1] - The company has a stable pricing strategy for its blood products, influenced by procurement policies and supply-demand dynamics [2] Group 2: Financial Performance - For the first half of 2024, the company achieved a revenue of CNY 4.252 billion, representing a year-on-year growth of 9.02% [2] - The net profit attributable to shareholders for the same period was CNY 1.241 billion, with a slight increase of 0.15% [2] - As of June 30, 2024, total assets amounted to CNY 32.373 billion, up by 1.39% from the previous year [2] - The net assets attributable to shareholders reached CNY 30.747 billion, reflecting a growth of 3.75% [2] Group 3: Strategic Partnerships - The company has a daily related transaction amount of USD 231 million with Grifols for human albumin products in the first half of 2024 [2] - The total expected related transaction amount for 2024 with Grifols is approximately USD 562 million [2] Group 4: Research and Development - The company employs a mixed R&D model, including independent development, collaborative projects, and technology introduction [3] - Clinical trials for the SR604 product are currently in Phase I, focusing on patient enrollment [4] Group 5: Market Expansion and Operations - The company is actively working on the resumption of operations for Guangxi Laishi and its associated plasma stations [3] - Plasma collection volume growth is influenced by various factors, including regional demographics and operational management capabilities [3] - The company is pursuing both organic growth and expansion through acquisitions to enhance plasma sourcing [3]

Investment Rating - The report maintains a "Buy" rating for Shanghai Laishi (002252) [1] Core Views - The company's H1 2024 performance met expectations with a revenue of 4.25 billion yuan, representing a 9% increase, and a net profit attributable to shareholders of 1.24 billion yuan, up 0.2% [3] - The growth in revenue was driven by a 2% increase in self-operated blood products revenue and an 18.9% increase in imported human albumin revenue [3] - The gross margin remained stable at 42% in Q2 2024, indicating effective adjustments in sales channels to mitigate price reductions in hospitals [3] - The report forecasts revenue growth for 2024-2026, estimating revenues of 8.81 billion yuan, 10.08 billion yuan, and 11.42 billion yuan, with net profits of 2.49 billion yuan, 2.81 billion yuan, and 3.17 billion yuan respectively [3] Summary by Sections Financial Performance - H1 2024 revenue was 4.25 billion yuan (+9%), with Q2 revenue at 2.2 billion yuan (+19.5%) [3] - H1 2024 net profit attributable to shareholders was 1.24 billion yuan (+0.2%), while Q2 net profit was 480 million yuan (-7%) [3] - The company experienced a decrease in non-recurring net profit by 6% in H1 2024 [3] Revenue Breakdown - Self-operated blood products revenue for H1 2024 was 2.25 billion yuan (+2%) [3] - Imported human albumin revenue reached 1.95 billion yuan (+18.9%), significantly contributing to overall revenue growth [3] Profitability Metrics - Q2 2024 gross margin was stable at 42%, reflecting the company's ability to manage costs effectively [3] - The report anticipates a recovery in profit margins in the second half of 2024 due to the one-time charitable donation impacting Q2 profits [3] Future Projections - Revenue projections for 2024-2026 are 8.81 billion yuan, 10.08 billion yuan, and 11.42 billion yuan respectively [4] - Net profit projections for the same period are 2.49 billion yuan, 2.81 billion yuan, and 3.17 billion yuan respectively [4] - The company is expected to maintain strong profitability in its self-operated blood products business while enhancing its market position through imported human albumin [3]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a revenue of 4.25 billion yuan for H1 2024, representing a year-on-year increase of 9%. Operating profit was 1.549 billion yuan, up 6% year-on-year, while net profit attributable to shareholders was 1.24 billion yuan, a slight increase of 0.15% year-on-year. The company plans to distribute a total dividend of 246 million yuan for the first half of the year [3] - Haier Group acquired a 20% stake in the company at a premium of 17.6% for 12.5 billion yuan, becoming the actual controller in July. This acquisition is expected to enhance the company's development through resource and management support, particularly in expanding plasma stations and improving operational management [3] - The company has 44 plasma stations, leading the industry in both the number of stations and plasma collection volume. The imported albumin business showed strong growth, with a revenue of 1.955 billion yuan, up 18.9% year-on-year [3] - The company has a comprehensive range of coagulation factor products and is developing innovative monoclonal antibody products for hemophilia. The sales of fibrinogen and PCC have been growing rapidly, and a clinical trial for a hemophilia monoclonal antibody is currently underway [3] - The blood products industry has significant growth potential and high concentration. The company is considered an undervalued leader in the blood products sector, with Haier Group expected to drive a new round of growth. The forecast for net profit attributable to shareholders is 2.442 billion yuan for 2024 and 2.632 billion yuan for 2025, with an expected net profit of 2.846 billion yuan in 2026. The current market value corresponds to a PE ratio of 19, 18, and 17 times for 2024-2026 [3] Financial Summary - Total revenue for 2023 is projected at 7.964 billion yuan, with a growth rate of 21.27%. The net profit attributable to shareholders is expected to be 1.779 billion yuan, with a decline of 5.35% year-on-year. The EPS is projected to be 0.27 yuan per share for 2023, with a PE ratio of 26.75 [2][8] - The company’s total assets are estimated to reach 34.185 billion yuan by 2024, with total liabilities of 2.223 billion yuan. The equity attributable to shareholders is projected to be 31.949 billion yuan [8] - The cash flow from operating activities for 2023 is expected to be 2.278 billion yuan, with a net increase in cash of 470 million yuan [9]